Research progress of immunoscore

doi:10.3760/cma.j.issn.1673-422X.2016.10.012

Abstract

Abstract: A methodology named "immunoscore" has been proposed in recent years. It has been demonstrated to be a prognostic factor superior to the Union for International Cancer ControlAmerican Joint Committee on Cancer (UICCAJCC) TNM classification. Over the past few years, it has gained a forefront position in colorectal cancer. It has the advantages of simple operation, low cost and high accuracy, and it is needed for individual therapy. However, it still has its limitations.

Key words: Neoplasm staging, Prognosis, Immunoscore

Zhao Xinru, Zhao Yuye, Li Guohong, Kan Xuan, Niu Zuoxing. Research progress of immunoscore[J]. Journal of International Oncology, 2016, 43(10): 772-774.

References

［1］ Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologicbased prognostic factors of colorectal cancers are associated with the state of the local immune reaction［J］. J Clin Oncol, 2011, 29(6): 610-618. DOI: 10.1200/JCO.2010.30.5425. ［2］孙成, 田志刚. 免疫评分:依据肿瘤组织免疫特性进行预后预测［J］. 中国肿瘤生物治疗杂志, 2015, 22(2): 177-182. DOI: 10.3872/j.issn.1007385X.2015.02.006. ［3］ Mlecnik B, Bindea G, Pagès F, et al. Tumor immunosurveillance in human cancers［J］. Cancer Metastasis Rev, 2011, 30(1): 5-12. DOI: 10.1007/s1055501192707. ［4］ Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care?［J］. Nat Rev Clin Oncol, 2012, 9(2): 119-123. DOI: 10.1038/nrclinonc.2011.157. ［5］ Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation［J］. Cell, 2011, 144(5): 646-674. DOI: 10.1016/j.cell.2011.02.013. ［6］ Zlobec I, Bihl M, Foerster A, et al. Comprehensive analysis of CpG island methylator phenotype (CIMP)high, low, and negative colorectal cancers based on protein marker expression and molecular features［J］. J Pathol, 2011, 225(3): 336-343. DOI: 10.1002/path.2879. ［7］ Laghi L, Malesci A. Microsatellite instability and therapeutic consequences in colorectal cancer［J］. Dig Dis, 2012, 30(3): 304-309. DOI: 10.1159/000337003. ［8］ Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ′immunoscore′ in the classification of malignant tumours［J］. J Pathol, 2014, 232(2): 199-209. DOI: 10.1002/path.4287. ［9］ Ingels A, Sanchez Salas RE, Ravery V, et al. Thelper 1 immunoreaction influences survival in muscleinvasive bladder cancer: proof of concept［J］. Ecancermedicalscience, 2014, 8: 486. DOI: 10.3332/ecancer.2014.486. ［10］ Van Den Boorn JG, Hartmann G. Turning tumors into vaccines: coopting the innate immune system［J］. Immunity, 2013, 39(1): 27-37. DOI: 10.1016/j.immuni.2013.07.011. ［11］ Angell H, Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer［J］. Curr Opin Immunol, 2013, 25(2): 261-267. DOI: 10.1016/j.coi.2013.03.004. ［12］ Galon J, Pagès F, Marincola FM, et al. Cancer classification using the immunoscore: a worldwide task force［J］. J Transl Med, 2012, 10(1): 205. DOI: 10.1186/1479587610205. ［13］ Fridman WH, Pagès F, SautèsFridman C, et al. The immune contexture in human tumours: impact on clinical outcome［J］. Nat Rev Cancer, 2012, 12(4): 298-306. DOI: 10.1038/nrc3245. ［14］ Galon J, Pagès F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer［J］. J Transl Med, 2012, 10(1): 1. DOI: 10.1186/14795876101. ［15］ Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma［J］. Clin Cancer Res, 2013, 19(5): 1225-1231. DOI: 10.1158/10780432.CCR121630. ［16］黄莹莹, 高晨燕. 免疫法治疗肿瘤的疗效评价的思考［J］. 中国临床药理学杂志, 2015, 31(13): 1338-1340. DOI: 10.13699/j.cnki.10016821.2015.13.037. ［17］ Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiPDL1 antibody in patients with advanced cancer［J］. N Engl J Med, 2012, 366(26): 2455-2465. DOI: 10.1056/NEJMoa1200694. ［18］ Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma［J］. N Engl J Med, 2011, 364(26): 2517-2526. DOI: 10.1056/NEJMoa1104621. ［19］ Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiPD1 antibody in cancer［J］. N Engl J Med, 2012, 366(26): 2443-2454. DOI: 10.1056/NEJMoa1200690. ［20］ Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer［J］. Immunity, 2013, 39(4): 782-795. DOI: 10.1016/j.immuni.2013.10.003.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[12]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[13]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[14]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469.
[15]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.